Article in Brain sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 4 institutions in 1 country.
Umberto ManeraUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.ORCID 0000-0002-9995-8133
Maria Claudia TorrieriAcademic Neurology Unit, San Luigi Gonzaga University Hospital, 10136 Orbassano, Italy.
Cristina MogliaUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.ORCID 0000-0001-7377-7222
Antonio CanosaUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.ORCID 0000-0001-5876-4079
Rosario VastaUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.
Francesca PalumboUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.
Enrico MatteoniUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.ORCID 0009-0008-2963-8821
Sara CabrasUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.ORCID 0000-0002-4988-2855
Maurizio GrassanoUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.
Alessandro BombaciUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.ORCID 0000-0002-3961-6780
Alessio MatteiS.C. Pneumologia, S. Croce and Carle Hospital, 12100 Cuneo, Italy.
Michela BellocchiaS.C. Pneumologia U, AOU Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
Giuseppe TabbiaS.C. Pneumologia U, AOU Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
Fulvia RibollaS.C. Pneumologia U, AOU Città della Salute e della Scienza di Torino, 10126 Turin, Italy.
Adriano ChiòUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.ORCID 0000-0001-9579-5341
Andrea CalvoUmberto Manera, ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126 Turin, Italy.ORCID 0000-0002-5122-7243
Azienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITUniversity of Turin · ITAzienda Sanitaria Ospedaliera S.Croce e Carle Cuneo · ITOspedale San Luigi Gonzaga · IT
Funding
European Commission's Health Seventh Framework Programme 259867European Union's Horizon 2020 GA101017598Italian Ministry of Education, University and Research 2017SNW5MBItalian Ministry of University and Research Department of Excellence grantJoint Programme-Neurodegenerative Disease Research Strength, ALS-Care and Brain-Mend projectsthe Italian Ministry of Health RF-2016-02362405
6 · The paper itself
Abstract
Respiratory failure assessment is among the most debatable research topics in amyotrophic lateral sclerosis (ALS) clinical research due to the wide heterogeneity of its presentation. Among the different pulmonary function tests (PFTs), maximal voluntary ventilation (MVV) has shown potential utility as a diagnostic and monitoring marker, able to capture early respiratory modification in neuromuscular disorders. In the present study, we explored calculated MVV (cMVV) as a prognostic biomarker in a center-based, retrospective ALS population belonging to the Piemonte and Valle d'Aosta registry for ALS (PARALS). A Spearman's correlation analysis with clinical data and PFTs showed a good correlation of cMVV with forced vital capacity (FVC) and a moderate correlation with some other features such as bulbar involvement, ALSFRS-R total score, blood oxygen (pO
Indexed as
amyotrophic lateral sclerosisforced vital capacitymaximal volume ventilationpulmonary function testsspirometry
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Calculated Maximal Volume Ventilation (cMVV) as a Marker of Early Respiratory Failure in Amyotrophic Lateral Sclerosis (ALS). · full record | OpenQuestion